Core Viewpoint - Bioventus Inc. reported strong financial results for Q4 and full-year 2025, highlighting above-market growth, improved margins, and a strengthened balance sheet, while providing optimistic guidance for 2026 [2][20]. Fourth Quarter 2025 Financial Results - Worldwide revenue for Q4 2025 was $157.9 million, a 10.0% increase on an organic basis, driven by double-digit growth in Pain Treatments and Surgical Solutions [3][9]. - Net income attributable to Bioventus was $14.8 million, compared to a net loss of $0.4 million in the prior-year period [4][34]. - Adjusted EBITDA for Q4 was $36.7 million, a 30% increase from $28.3 million in the prior-year period [4]. - GAAP earnings per diluted share improved to $0.21 from $0.00 in the prior-year period, while adjusted EPS was $0.24, slightly down from $0.26 [5]. Full-Year 2025 Financial Results - Total worldwide revenue for 2025 was $568.1 million, a decrease of 0.9% compared to the prior year, primarily due to the divestiture of the Advanced Rehabilitation Business; however, organic revenue grew by 7.5% [6][15]. - Full-year net income attributable to Bioventus was $22.7 million, a significant improvement from a net loss of $36.1 million in the previous year [7][34]. - Adjusted EBITDA for the full year was $116.3 million, up 6.8% from $108.9 million [7]. - GAAP earnings per diluted share for the year were $0.33, compared to a loss of $0.56 in the prior year, while adjusted EPS was $0.68, reflecting a 21.4% increase [8]. Revenue by Business Segment - Pain Treatments generated $79.7 million in Q4, a 15.1% increase, driven by strong demand for hyaluronic acid therapies for knee osteoarthritis [10][15]. - Surgical Solutions revenue was $55.5 million, up 3.4%, attributed to higher U.S. demand for Bone Graft Substitutes [11]. - Restorative Therapies revenue was $22.7 million, reflecting a 26.0% decline due to the divestiture of the Advanced Rehabilitation Business, but showed 10.3% organic growth [11][16]. Geographic Revenue Breakdown - U.S. revenue for Q4 was $139.5 million, a 3.2% increase, with organic growth of 10.1% [13]. - International revenue was $18.4 million, a slight decrease of 0.1%, but increased 9.5% on an organic basis [13][19]. 2026 Financial Guidance - Bioventus expects 2026 revenue between $600 million and $610 million, reflecting growth of approximately 6% to 7% [22]. - Adjusted EPS is projected to be between $0.73 and $0.77, indicating an increase of approximately 7% to 13% [22].

Core Viewpoint - Bioventus Inc. reported a decline in revenue for the first quarter of 2025, primarily due to the divestiture of its Advanced Rehabilitation Business, but achieved organic revenue growth across all business segments, indicating resilience in its strategic execution despite macroeconomic challenges [2][6]. Financial Performance - Worldwide revenue for Q1 2025 was $123.9 million, a decrease of 4.3% from $129.5 million in the same period last year, largely impacted by the divestiture [2][5]. - Organic revenue increased by 5.0%, reflecting positive growth across all three business segments [2][6]. - The net loss attributable to Bioventus Inc. was $2.6 million, an improvement from a net loss of $4.9 million in the prior-year period [3][4]. - Adjusted EBITDA for the quarter was $19.2 million, down from $22.6 million in the previous year, primarily due to the divestiture and planned growth investments [3][6]. Revenue Breakdown by Business - U.S. revenue from Pain Treatments was $52.7 million, up 4.0% year-over-year, while Surgical Solutions revenue increased by 6.5% to $40.8 million [5][8]. - Restorative Therapies revenue fell by 32.9% to $17.0 million, significantly affected by the divestiture of the Advanced Rehabilitation Business [5][9]. - International revenue totaled $13.4 million, a decline of 12.0%, with Pain Treatments and Surgical Solutions showing modest growth, while Restorative Therapies revenue dropped by 47.1% [5][9]. Strategic Developments - The company reiterated its financial guidance for 2025, expecting net sales between $560 million and $570 million, reflecting organic growth of approximately 6.1% to 8.0% when accounting for the divestiture [10][13]. - Adjusted EBITDA guidance for 2025 is set between $112 million and $116 million, indicating a potential increase in Adjusted EBITDA margin compared to 2024 [10][13]. - Non-GAAP EPS is projected to be between $0.64 and $0.68, representing a growth of 30.6% to 38.8% [10][13].